Skip to content

Effect of Mesenchimal Stem Cell in Rotator Cuff Tendinopathy

Comparison of Ultrasound-Guided Local Corticosteroid Injection versus Mesenchymal Stem Cell Origin of Adipocytes ( Allogeneic ) in patient with Rotator Cuff Tendinopathy

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20151017024572N21
Enrollment
30
Registered
2020-01-09
Start date
2020-01-21
Completion date
Unknown
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Shoulder tendinopathy. Impingement syndrome of shoulder

Interventions

Intervention 1: Intervention group: Allogeneic Stem Cell Injection in the area with partial rupture with Ultrasound-guided Lateral Approach. Intervention 2: Control group: Ultrasound-guided injection

Sponsors

Iran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: The presence of tendinopathy in patients with positive shoulder specific tests including: Neer test, Hawkins test Visual Analogue Scale more than 4 Lack of history of poor control Diabetes, coagulopathy, fractures, rheumatologic diseases, tumors and systemic disease infection No history of shoulder injections in the last 4 months Patient's age 18 to 65 years No pregnancy or decision to become pregnant Lack of risk factor for intra articular injection such as coagulation disorders or Use of anticoagulants Lack of mental disorder Patient willingness to participate in research project

Exclusion criteria

Exclusion criteria: Patients who have not been followed for any reason Changes in the patient's treatment according to the physician or Other treatment by the patient during the study History of shoulder surgery Complete rotator cuff rupture History of cervical radiculopathy Myofascial trigger points

Design outcomes

Primary

MeasureTime frame
The severity of symptoms. Timepoint: Zero, two weeks , three months , six months later (Since the injection). Method of measurement: Visual Analog Scale (VAS).;Shoulder Pain and Disability. Timepoint: Zero, two weeks , three months , six months later (Since the injection). Method of measurement: Quick Disabilities of Arm, Shoulder & Hand (Quick DASH).

Secondary

MeasureTime frame
Side effects. Timepoint: 30 minutes and tow weeks (Since the injection). Method of measurement: Physical examination.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNariman samadaeian

Iran University of Medical Sciences

nariman.samadaeian@gmail.com+98 21 8214 1201

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026